Pimasertib, a second-generation MEK1/2 inhibitor, also showed an improvement in the PFS over dacarbazine (13.0 vs. 6.9 weeks) in a phase 2 study in NRAS mutant melanomas; however, the OS was similar [102]. The gene discussed is NRAS; the disease is melanoma.